Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The study is a randomized, open-label safety study comparing the use of anidulafungin (200 mg
i.v. as initial dose and 100 mg/d i.v. in subsequent doses) vs liposomal amphotericin B (3
mg/kg/d i.v.) in hepatic transplant recipients who have high risk of fungal infection.
Phase:
Phase 4
Details
Lead Sponsor:
Fundacion SEIMC-GESIDA
Collaborator:
Pfizer
Treatments:
Amphotericin B Anidulafungin Echinocandins Liposomal amphotericin B